{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:09:54Z","timestamp":1790082594517,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00270-017-1630-4","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T16:58:54Z","timestamp":1493312334000},"page":"1196-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prospective Clinical and Pharmacological Evaluation of the Delcath System\u2019s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan"],"prefix":"10.1007","volume":"40","author":[{"given":"Eleonora M.","family":"de Leede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Burgmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Susanna","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred G. J.","family":"Tijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Vuyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian R.","family":"van Erkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J. H.","family":"van der Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"issue":"4","key":"1630_CR1","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol. 2016;23(4):1309\u201319. doi:\n                    10.1245\/s10434-015-4968-3\n                    \n                  .","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1630_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archsurg.138.3.325","volume":"138","author":"E Savier","year":"2003","unstructured":"Savier E, Azoulay D, Huguet E, Lokiec F, Gil-Delgado M, Bismuth H. Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study. Arch Surg. 2003;138(3):325\u201332.","journal-title":"Arch Surg"},{"issue":"1","key":"1630_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/01.sla.0000103133.03688.3d","volume":"239","author":"Y Ku","year":"2004","unstructured":"Ku Y, Iwasaki T, Tominaga M, Fukumoto T, Takahashi T, Kido M, et al. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg. 2004;239(1):53\u201360. doi:\n                    10.1097\/01.sla.0000103133.03688.3d\n                    \n                  .","journal-title":"Ann Surg"},{"issue":"3","key":"1630_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1245\/s10434-007-9781-1","volume":"15","author":"N Miao","year":"2008","unstructured":"Miao N, Pingpank JF, Alexander HR, Steinberg SM, Beresneva T, Quezado ZM. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol. 2008;15(3):815\u201323. doi:\n                    10.1245\/s10434-007-9781-1\n                    \n                  .","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1630_CR5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jso.23501","volume":"109","author":"MR Forster","year":"2014","unstructured":"Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol. 2014;109(5):434\u20139. doi:\n                    10.1002\/jso.23501\n                    \n                  .","journal-title":"J Surg Oncol"},{"issue":"3","key":"1630_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.jvca.2013.07.022","volume":"28","author":"M Fitzpatrick","year":"2014","unstructured":"Fitzpatrick M, Richard Alexander H, Deshpande SP, Martz DG Jr, McCormick B, Grigore AM. Use of partial venovenous cardiopulmonary bypass in percutaneous hepatic perfusion for patients with diffuse, isolated liver metastases: a case series. J Cardiothorac Vasc Anesth. 2014;28(3):647\u201351. doi:\n                    10.1053\/j.jvca.2013.07.022\n                    \n                  .","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"10","key":"1630_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1055\/s-0034-1366081","volume":"186","author":"TJ Vogl","year":"2014","unstructured":"Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2014;186(10):937\u201344. doi:\n                    10.1055\/s-0034-1366081\n                    \n                  .","journal-title":"RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin"},{"issue":"6","key":"1630_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00270-015-1276-z","volume":"39","author":"MC Burgmans","year":"2016","unstructured":"Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous Isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Interv Radiol. 2016;39(6):801\u201314. doi:\n                    10.1007\/s00270-015-1276-z\n                    \n                  .","journal-title":"Cardiovasc Interv Radiol"},{"issue":"15","key":"1630_CR9","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","volume":"23","author":"JF Pingpank","year":"2005","unstructured":"Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23(15):3465\u201374. doi:\n                    10.1200\/JCO.2005.00.927\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"3","key":"1630_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00270-013-0826-5","volume":"37","author":"FM Moeslein","year":"2014","unstructured":"Moeslein FM, McAndrew EG, Appling WM, Hryniewich NE, Jarvis KD, Markos SM, et al. Evaluation of Delcath Systems\u2019 Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion. Cardiovasc Interv Radiol. 2014;37(3):763\u20139. doi:\n                    10.1007\/s00270-013-0826-5\n                    \n                  .","journal-title":"Cardiovasc Interv Radiol"},{"issue":"7","key":"1630_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/bmc.273","volume":"17","author":"RW Sparidans","year":"2003","unstructured":"Sparidans RW, Silvertand L, Dost F, Rothbarth J, Mulder GJ, Schellens JH, et al. Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. Biomed Chromatogr. 2003;17(7):458\u201364. doi:\n                    10.1002\/bmc.273\n                    \n                  .","journal-title":"Biomed Chromatogr"},{"issue":"10","key":"1630_CR12","doi-asserted-by":"publisher","first-page":"1364-71 e1","DOI":"10.1016\/j.jvir.2011.06.007","volume":"22","author":"MH Abdelmaksoud","year":"2011","unstructured":"Abdelmaksoud MH, Louie JD, Kothary N, Hwang GL, Kuo WT, Hofmann LV, et al. Consolidation of hepatic arterial inflow by embolization of variant hepatic arteries in preparation for yttrium-90 radioembolization. J Vasc Interv Radiol. 2011;22(10):1364-71 e1. doi:\n                    10.1016\/j.jvir.2011.06.014\n                    \n                  .","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"1630_CR13","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00270-016-1310-9","volume":"39","author":"AS Borggreve","year":"2016","unstructured":"Borggreve AS, Landman AJ, Vissers CM, De Jong CD, Lam MG, Monninkhof EM, et al. Radioembolization: Is prophylactic embolization of hepaticoenteric arteries necessary? A systematic review. Cardiovasc Interv Radiol. 2016;39(5):696\u2013704. doi:\n                    10.1007\/s00270-016-1310-9\n                    \n                  .","journal-title":"Cardiovasc Interv Radiol"},{"issue":"2","key":"1630_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/pcmr.12304","volume":"28","author":"JJ Luke","year":"2015","unstructured":"Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015;28(2):135\u201347. doi:\n                    10.1111\/pcmr.12304\n                    \n                  .","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"1630_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/s-0033-1333652","volume":"30","author":"DJ Eschelman","year":"2013","unstructured":"Eschelman DJ, Gonsalves CF, Sato T. Transhepatic therapies for metastatic uveal melanoma. Semin Interv Radiol. 2013;30(1):39\u201348. doi:\n                    10.1055\/s-0033-1333652\n                    \n                  .","journal-title":"Semin Interv Radiol"},{"issue":"2","key":"1630_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/CMR.0000000000000129","volume":"25","author":"S Valpione","year":"2015","unstructured":"Valpione S, Aliberti C, Parrozzani R, Bazzi M, Pigozzo J, Midena E, et al. A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. Melanoma Res. 2015;25(2):164\u20138. doi:\n                    10.1097\/CMR.0000000000000129\n                    \n                  .","journal-title":"Melanoma Res"}],"updated-by":[{"DOI":"10.1007\/s00270-017-1766-2","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000}}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00270-017-1630-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-017-1630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-017-1630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T19:46:40Z","timestamp":1552679200000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00270-017-1630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1007\/s00270-017-1630-4","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s00270-017-1766-2","asserted-by":"object"}]},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]},"assertion":[{"value":"7 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An erratum to this article has been published.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Delcath Systems provided in-kind support and an educational grant for the conduct of the study. Three of the authors received travel fees to attend expert meetings sponsored by Delcath.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional and\/or National Research Committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}